Home › NCT05390515

Psoriatic Immune Response to Tildrakizumab

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* 18 years of age or older
* Patients with moderate-severe psoriasis or \> 5% body surface area affected.

Exclusion Criteria:

* taking systemic immunosuppressives in the last 4 weeks
* pregnancy
* severe immunodeficiency (either from genetic or infectious causes).
* tuberculosis or other active serious infection
* active systemic malignancy.
* breast-feeding
* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

About the study

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

What is being tested

• Tildrakizumab Prefilled Syringe (drug)

Sponsor: University of California, San Francisco · Participants: 10 · Started: Sep 1, 2022

Contact the study team

• Raymond Cho, MD, PhD · Phone: 415-575-0524

Official record on ClinicalTrials.gov — NCT05390515

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.